



Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

R. B. Verheijen¹ · E. L. Swart¹ · J. H. Beijnen^{1,2} · J. H. M. Schellens^{2,3} · A. D. R. Huitema^{1,4} · N. Steeghs³

Published online: 11 June 2020

© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Correction to:

Cancer Chemother Pharmacol (2017) 80:1171–1178

<https://doi.org/10.1007/s00280-017-3463-x>

In the original publication of the article, the second author name has been misspelled as L. E. Swart. The correct name should read as E. L. Swart.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s00280-017-3463-x>.

✉ R. B. Verheijen
r.verheijen@nki.nl

- ¹ Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
- ² Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
- ³ Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands
- ⁴ Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands